Drug intelligence / Profile preview

Butang

Development stage: Unknown
Lead developer: Instituto Butantan
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

Butang is a recombinant hepatitis B vaccine manufactured by Instituto Butantan in Brazil. It is a yeast-derived recombinant protein adsorbed to an aluminum-containing immunostimulant. The vaccine works by inducing an immune response, specifically the production of anti-HBs antibodies, to protect against Hepatitis B virus infection. It is widely used in Brazil and has been evaluated for safety and immunogenicity across various age groups, including neonates, children, adolescents, and adults.

Brand names: Butang
Other names: Hepatitis B vaccine (recombinant)Butantan Hepatitis B vaccine

Targets

HBsAg (Hepatitis B surface antigen)

Beyond the preview

Go deeper on Butang.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Butang.

Explore the full profile